194 related articles for article (PubMed ID: 33144587)
1. Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies.
de Vries G; Rosas-Plaza X; Meersma GJ; Leeuwenburgh VC; Kok K; Suurmeijer AJH; van Vugt MATM; Gietema JA; de Jong S
Sci Rep; 2020 Nov; 10(1):18938. PubMed ID: 33144587
[TBL] [Abstract][Full Text] [Related]
2. Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday C; Litchfield K; Proszek PZ; Cornish AJ; Santo F; Levy M; Macintyre G; Holryod A; Broderick P; Dudakia D; Benton B; Bakir MA; Hiley C; Grist E; Swanton C; Huddart R; Powles T; Chowdhury S; Shipley J; O'Connor S; Brenton JD; Reid A; de Castro DG; Houlston RS; Turnbull C
Nat Commun; 2020 May; 11(1):2189. PubMed ID: 32366847
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
[TBL] [Abstract][Full Text] [Related]
4. EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.
Chen KS; Fustino NJ; Shukla AA; Stroup EK; Budhipramono A; Ateek C; Stuart SH; Yamaguchi K; Kapur P; Frazier AL; Lum L; Looijenga LHJ; Laetsch TW; Rakheja D; Amatruda JF
Mol Cancer Ther; 2018 May; 17(5):1079-1089. PubMed ID: 29483210
[TBL] [Abstract][Full Text] [Related]
5. Genomic evolution and chemoresistance in germ-cell tumours.
Taylor-Weiner A; Zack T; O'Donnell E; Guerriero JL; Bernard B; Reddy A; Han GC; AlDubayan S; Amin-Mansour A; Schumacher SE; Litchfield K; Turnbull C; Gabriel S; Beroukhim R; Getz G; Carter SL; Hirsch MS; Letai A; Sweeney C; Van Allen EM
Nature; 2016 Nov; 540(7631):114-118. PubMed ID: 27905446
[TBL] [Abstract][Full Text] [Related]
6. Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.
Li LY; Kim HJ; Park SA; Lee SH; Kim LK; Lee JY; Kim S; Kim YT; Kim SW; Nam EJ
Cancer Res Treat; 2019 Jul; 51(3):1117-1127. PubMed ID: 30428638
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
8. The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells.
Camacho-Moll ME; Macdonald J; Looijenga LHJ; Rimmer MP; Donat R; Marwick JA; Shukla CJ; Carragher N; Jørgensen A; Mitchell RT
BMC Cancer; 2019 Nov; 19(1):1124. PubMed ID: 31744479
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model.
Luo M; He Y; Xie B; Li S; Gan F; Zhang S; Luo P
Pediatr Surg Int; 2021 Aug; 37(8):1031-1040. PubMed ID: 34031745
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
11. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
[TBL] [Abstract][Full Text] [Related]
12. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Woo XY; Giordano J; Srivastava A; Zhao ZM; Lloyd MW; de Bruijn R; Suh YS; Patidar R; Chen L; Scherer S; Bailey MH; Yang CH; Cortes-Sanchez E; Xi Y; Wang J; Wickramasinghe J; Kossenkov AV; Rebecca VW; Sun H; Mashl RJ; Davies SR; Jeon R; Frech C; Randjelovic J; Rosains J; Galimi F; Bertotti A; Lafferty A; O'Farrell AC; Modave E; Lambrechts D; Ter Brugge P; Serra V; Marangoni E; El Botty R; Kim H; Kim JI; Yang HK; Lee C; Dean DA; Davis-Dusenbery B; Evrard YA; Doroshow JH; Welm AL; Welm BE; Lewis MT; Fang B; Roth JA; Meric-Bernstam F; Herlyn M; Davies MA; Ding L; Li S; Govindan R; Isella C; Moscow JA; Trusolino L; Byrne AT; Jonkers J; Bult CJ; Medico E; Chuang JH; ;
Nat Genet; 2021 Jan; 53(1):86-99. PubMed ID: 33414553
[TBL] [Abstract][Full Text] [Related]
13. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities.
de Vries G; Rosas-Plaza X; van Vugt MATM; Gietema JA; de Jong S
Cancer Treat Rev; 2020 Aug; 88():102054. PubMed ID: 32593915
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.
Knudsen ES; Balaji U; Mannakee B; Vail P; Eslinger C; Moxom C; Mansour J; Witkiewicz AK
Gut; 2018 Mar; 67(3):508-520. PubMed ID: 28073890
[TBL] [Abstract][Full Text] [Related]
15. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G
Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802
[TBL] [Abstract][Full Text] [Related]
16. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
17. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
Bagrodia A; Lee BH; Lee W; Cha EK; Sfakianos JP; Iyer G; Pietzak EJ; Gao SP; Zabor EC; Ostrovnaya I; Kaffenberger SD; Syed A; Arcila ME; Chaganti RS; Kundra R; Eng J; Hreiki J; Vacic V; Arora K; Oschwald DM; Berger MF; Bajorin DF; Bains MS; Schultz N; Reuter VE; Sheinfeld J; Bosl GJ; Al-Ahmadie HA; Solit DB; Feldman DR
J Clin Oncol; 2016 Nov; 34(33):4000-4007. PubMed ID: 27646943
[TBL] [Abstract][Full Text] [Related]
18. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Berney DM; Shamash J; Gaffney J; Jordan S; Oliver RT
Br J Cancer; 2002 Sep; 87(6):624-9. PubMed ID: 12237772
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
